Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2021-08-23 08:30:00
Oslo, Norway, August 23, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, will hold a webcast to discuss the results for the first half
of 2021 on August 26, 2021 at 10 am CEST.
The webcast will be in English and may be viewed here:
https://forms.office.com/r/7c9HHCDRPT. Further, the slide presentation will be
available on Vaccibody's website at https://www.vaccibody.com
About Vaccibody
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies for the
treatment cancer and infectious diseases. Vaccibody's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen-specific immune responses
and elicit efficacious clinical responses. Its lead product candidates include
VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to
Genentech and is in Phase Ib for the treatment of locally advanced and
metastatic tumors and Phase I/IIa for the treatment of melanoma, lung-, head and
neck, renal-, and bladder cancer